A rationale for the use of proton pump inhibitors as antineoplastic agents

Current Pharmaceutical Design

Volumn 18, Issue 10, 2012, Pages 1395-1406

  de Milito, Angelo ^a,b   Marino, Maria Lucia ^b   Fais, Stefano ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Cancer therapy; Omeprazole; Proton pump inhibitors; Tumor pH; V atpase

Indexed keywords

ACETYL COENZYME A; ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; HYPOXIA INDUCIBLE FACTOR 1; PROTON PUMP INHIBITOR; PYRUVIC ACID;

ACIDITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER INVASION; CANCER RESISTANCE; CARCINOGENESIS; CELL HYPOXIA; CELL METABOLISM; CELL PH; CYTOPLASM; CYTOTOXICITY; DRUG DISCRIMINATION; DRUG METABOLISM; DRUG PENETRATION; DRUG TUMOR LEVEL; DYSPLASIA; ENZYME ACTIVITY; EXTRACELLULAR SPACE; GENE ACTIVATION; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; MALIGNANT TRANSFORMATION; ONCOGENE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TUMOR LOCALIZATION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; UPREGULATION;

EID: 84857749232     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799504911     Document Type: Review

References (162)

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61(5): 759-767.
2. Gillies RJ, Gatenby RA. Hypoxia and adaptive landscapes in the evolution of carcinogenesis. Cancer Metastasis Rev 2007; 26(2): 311-317.
3. Folkman J, Hahnfeldt P, Hlatky L. Cancer: looking outside the genome. Nat Rev Mol Cell Biol 2000; 1(1): 76-79.
4. Aplin AE, Kaplan FM, Shao Y. Mechanisms of Resistance to RAF Inhibitors in Melanoma. J Invest Dermatol 2011 May 19.
5. Wagle N, Emery C, Berger MF, et al. Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling. J Clin Oncol 2011; 29(22): 3085-3096.
6. Chabner BA, Roberts TG, Jr. Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer 2005; 5(1): 65-72.
7. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15(3): 232-239.
8. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15(3): 220-231.
9. Gatenby RA. A change of strategy in the war on cancer. Nature 2009; 459(7246): 508-9.
10. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011; 11(2): 85-95.
11. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008; 13(6): 472-442.
12. Warburg O. On the origin of cancer cells. Science 1956; 123(3191): 309-314.
13. Cardone RA, Casavola V, Reshkin SJ. The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat Rev Cancer 2005; 5(10): 786-795.
14. De Milito A, Fais S. Tumor Acidity, Chemoresistance and Proton Pump Inhibitors. Future Oncology 2005; 1(6): 779-786.
15. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4(11): 891-899.
16. Raghunand N, Gillies RJ. pH and chemotherapy. Novartis Found Symp 2001; 240: 199-211; discussion 265-298.
17. Raghunand N, Mahoney BP, Gillies RJ. Tumor acidity, ion trapping and chemotherapeutics. II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents. Biochem Pharmacol 2003; 66(7): 1219-1229.
18. Fais S, De Milito A, You H, Qin W. Targeting vacuolar H+-ATPases as a new strategy against cancer. Cancer Res 2007; 67(22): 10627-10630.
19. Gerweck LE. Tumor pH: implications for treatment and novel drug design. Semin Radiat Oncol 1998; 8(3): 176-182.
20. Harguindey S, Arranz JL, Wahl ML, Orive G, Reshkin SJ. Proton transport inhibitors as potentially selective anticancer drugs. Anticancer Res 2009; 29(6): 2127-2136.
21. Izumi H, Torigoe T, Ishiguchi H, et al. Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treat Rev 2003; 29(6): 541-549.
22. Robey IF, Baggett BK, Kirkpatrick ND, et al. Bicarbonate Increases Tumor pH and Inhibits Spontaneous Metastases. Cancer Res 2009 Mar 10.
23. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 1989; 49(16): 4373-4384.
24. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 2008; 49 Suppl 2: 24S-42S.
25. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324(5930): 1029-1033.
26. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7(1): 11-20.
27. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell 2008; 134(5): 703-707.
28. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006; 441(7092): 437-443.
29. Hersey P, Watts RN, Zhang XD, Hackett J. Metabolic approaches to treatment of melanoma. Clin Cancer Res 2009; 15(21): 6490-6494.
30. Tennant DA, Duran RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 2010; 10(4): 267-277.
31. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008; 7(2): 168-181.
32. Porporato PE, Dhup S, Dadhich RK, Copetti T, Sonveaux P. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol 2011; 2: 49.
33. Chi SL, Pizzo SV. Angiostatin is directly cytotoxic to tumor cells at low extracellular pH: a mechanism dependent on cell surface-associated ATP synthase. Cancer Res 2006; 66(2): 875-882.
34. Nishi T, Forgac M. The vacuolar (H+)-ATPases--nature's most versatile proton pumps. Nat Rev Mol Cell Biol 2002; 3(2): 94-103.
35. Marshansky V, Futai M. The V-type H+-ATPase in vesicular trafficking: targeting, regulation and function. Curr Opin Cell Biol 2008; 20(4): 415-426.
36. Martinez-Zaguilan R, Lynch RM, Martinez GM, Gillies RJ. Vacuolar-type H(+)-ATPases are functionally expressed in plasma membranes of human tumor cells. Am J Physiol 1993; 265(4 Pt 1): C1015-C1029.
37. Martinez-Zaguilan R, Raghunand N, Lynch RM, et al. pH and drug resistance. I. Functional expression of plasmalemmal V-type H+-ATPase in drug-resistant human breast carcinoma cell lines. Biochem Pharmacol 1999; 57(9): 1037-1046.
38. Hinton A, Sennoune SR, Bond S, et al. Function of a subunit isoforms of the V-ATPase in pH homeostasis and In vitro invasion of MDA-MB231 human breast cancer cells. J Biol Chem 2009 Apr 14.
39. Martinez-Zaguilan R, Seftor EA, Seftor RE, Chu YW, Gillies RJ, Hendrix MJ. Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 1996; 14(2): 176-86.
40. Rofstad EK, Mathiesen B, Kindem K, Galappathi K. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res 2006; 66(13): 6699-6707.
41. Sennoune SR, Bakunts K, Martinez GM, et al. Vacuolar H+-ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. Am J Physiol Cell Physiol 2004; 286(6): C1443-C1452.
42. Raghunand N, Altbach MI, van Sluis R, et al. Plasmalemmal pH-gradients in drug-sensitive and drug-resistant MCF-7 human breast carcinoma xenografts measured by 31P magnetic resonance spectroscopy. Biochem Pharmacol 1999; 57(3): 309-312.
43. Altan N, Chen Y, Schindler M, Simon SM. Defective acidification in human breast tumor cells and implications for chemotherapy. J Exp Med 1998; 187(10): 1583-1598.
44. Luciani F, Spada M, De Milito A, et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst 2004; 96(22): 1702-1713.
45. Ouar Z, Bens M, Vignes C, et al. Inhibitors of vacuolar H+-ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cells. Biochem J 2003; 370(Pt 1): 185-193.
46. Nakashima S, Hiraku Y, Tada-Oikawa S, et al. Vacuolar H+-ATPase inhibitor induces apoptosis via lysosomal dysfunction in the human gastric cancer cell line MKN-1. J Biochem (Tokyo) 2003; 134(3): 359-364.
47. Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, Rey JM, Garcia-Garcia A. V-ATPase inhibitors and implication in cancer treatment. Cancer Treat Rev 2009; 35(8): 707-713.
48. Hinton A, Bond S, Forgac M. V-ATPase functions in normal and disease processes. Pflugers Arch 2009; 457(3): 589-598.
49. De Milito A, Canese R, Marino ML, et al. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer 2010; 127(1): 207-219.
50. De Milito A, Iessi E, Logozzi M, et al. Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. Cancer Res 2007; 67(11): 5408-5417.
51. Lu X, Qin W, Li J, et al. The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump. Cancer Res 2005; 65(15): 6843-6849.
52. Morita T, Nagaki T, Fukuda I, Okumura K. Clastogenicity of low pH to various cultured mammalian cells. Mutat Res 1992; 268(2): 297-305.
53. Gillies RJ, Raghunand N, Karczmar GS, Bhujwalla ZM. MRI of the tumor microenvironment. J Magn Reson Imaging 2002; 16(4): 430-450.
54. Gatenby RA, Gillies RJ. A microenvironmental model of carcinogenesis. Nat Rev Cancer 2008; 8(1): 56-61.
55. Orive G, Reshkin SJ, Harguindey S, Pedraz JL. Hydrogen ion dynamics and the Na+/H+ exchanger in cancer angiogenesis and antiangiogenesis. Br J Cancer 2003; 89(8): 1395-1399.
56. Yuan J, Narayanan L, Rockwell S, Glazer PM. Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH. Cancer Res 2000; 60(16): 4372-4376.
57. Moellering RE, Black KC, Krishnamurty C, et al. Acid treatment of melanoma cells selects for invasive phenotypes. Clin Exp Metastasis 2008; 25(4): 411-425.
58. Smallbone K, Gavaghan DJ, Gatenby RA, Maini PK. The role of acidity in solid tumour growth and invasion. J Theor Biol 2005; 235(4): 476-484.
59. Bourguignon LY, Singleton PA, Diedrich F, Stern R, Gilad E. CD44 interaction with Na+-H+ exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. J Biol Chem 2004; 279(26): 26991-27007.
60. Busco G, Cardone RA, Greco MR, et al. NHE1 promotes invadopodial ECM proteolysis through acidification of the peri-invadopodial space. Faseb J 2010 Jun 14.
61. Fukumura D, Xu L, Chen Y, Gohongi T, Seed B, Jain RK. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res 2001; 61(16): 6020-6024.
62. Giusti I, D'Ascenzo S, Millimaggi D, et al. Cathepsin B mediates the pH-dependent proinvasive activity of tumor-shed microvesicles. Neoplasia 2008; 10(5): 481-488.
63. Taraboletti G, D'Ascenzo S, Giusti I, et al. Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH. Neoplasia 2006; 8(2): 96-103.
64. Xu L, Fidler IJ. Acidic pH-induced elevation in interleukin 8 expression by human ovarian carcinoma cells. Cancer Res 2000; 60(16): 4610-4616.
65. Xu L, Fukumura D, Jain RK. Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: mechanism of low pH-induced VEGF. J Biol Chem 2002; 277(13): 11368-11374.
66. Silva AS, Yunes JA, Gillies RJ, Gatenby RA. The potential role of systemic buffers in reducing intratumoral extracellular pH and acid-mediated invasion. Cancer Res 2009; 69(6): 2677-2684.
67. Rich IN, Worthington-White D, Garden OA, Musk P. Apoptosis of leukemic cells accompanies reduction in intracellular pH after targeted inhibition of the Na(+)/H(+) exchanger. Blood 2000; 95(4): 1427-1434.
68. Wahl ML, Owen JA, Burd R, et al. Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol Cancer Ther 2002; 1(8): 617-628.
69. Gillies RJ, Liu Z, Bhujwalla Z. 31P-MRS measurements of extracellular pH of tumors using 3-aminopropylphosphonate. Am J Physiol 1994; 267(1 Pt 1): C195-C203.
70. Hjelmeland AB, Wu Q, Heddleston JM, et al. Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ 2011; 18(5): 829-840.
71. Mahoney BP, Raghunand N, Baggett B, Gillies RJ. Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol 2003; 66(7): 1207-1218.
72. Simon S, Roy D, Schindler M. Intracellular pH and the control of multidrug resistance. Proc Natl Acad Sci U S A 1994; 91(3): 1128-1132.
73. Gerweck LE, Vijayappa S, Kozin S. Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. Mol Cancer Ther 2006; 5(5): 1275-1279.
74. Raghunand N, Gillies RJ. pH and drug resistance in tumors. Drug Resist Updat 2000; 3(1): 39-47.
75. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007; 99(19): 1441-1454.
76. Gabr A, Kuin A, Aalders M, El-Gawly H, Smets LA. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH. Cancer Res 1997 Nov 1; 57(21): 4811-4816.
77. Adams DJ. The impact of tumor physiology on camptothecin-based drug development. Curr Med Chem Anticancer Agents 2005; 5(1): 1-13.
78. Thews O, Gassner B, Kelleher DK, Schwerdt G, Gekle M. Impact of extracellular acidity on the activity of P-glycoprotein and the cytotoxicity of chemotherapeutic drugs. Neoplasia 2006; 8(2): 143-152.
79. Rauch C, Pluen A. Multi drug resistance-dependent vacuum cleaner functionality potentially driven by the interactions between endocytosis, drug size and Pgp-like transporters surface density. Eur Biophys J 2007; 36(2): 121-131.
80. Rauch C. Toward a mechanical control of drug delivery. On the relationship between Lipinski's 2nd rule and cytosolic pH changes in doxorubicin resistance levels in cancer cells: a comparison to published data. Eur Biophys J 2009; 38(7): 829-846.
81. Rauch C. The multi of drug resistance explained by oscillating drug transporters, drug-membrane physical interactions and spatial dimensionality. Cell Biochem Biophys 2011; 61(1): 103-113.
82. Raghunand N, He X, van Sluis R, et al. Enhancement of chemotherapy by manipulation of tumour pH. Br J Cancer 1999; 80(7): 1005-1011.
83. Ouar Z, Lacave R, Bens M, Vandewalle A. Mechanisms of altered sequestration and efflux of chemotherapeutic drugs by multidrug-resistant cells. Cell Biol Toxicol 1999; 15(2): 91-100.
84. Belhoussine R, Morjani H, Sharonov S, Ploton D, Manfait M. Characterization of intracellular pH gradients in human multidrug-resistant tumor cells by means of scanning microspectrofluorometry and dual-emission-ratio probes. Int J Cancer 1999; 81(1): 81-90.
85. Miraglia E, Viarisio D, Riganti C, Costamagna C, Ghigo D, Bosia A. Na+/H+ exchanger activity is increased in doxorubicin-resistant human colon cancer cells and its modulation modifies the sensitivity of the cells to doxorubicin. Int J Cancer 2005 Jul 20; 115(6): 924-929.
86. Goossens JF, Henichart JP, Dassonneville L, Facompre M, Bailly C. Relation between intracellular acidification and camptothecin-induced apoptosis in leukemia cells. Eur J Pharm Sci 2000; 10(2): 125-131.
87. Gottlieb RA, Nordberg J, Skowronski E, Babior BM. Apoptosis induced in Jurkat cells by several agents is preceded by intracellular acidification. Proc Natl Acad Sci U S A 1996 Jan 23; 93(2): 654-658.
88. Marches R, Vitetta ES, Uhr JW. A role for intracellular pH in membrane IgM-mediated cell death of human B lymphomas. Proc Natl Acad Sci U S A 2001; 98(6): 3434-3439.
89. Nilsson C, Johansson U, Johansson AC, Kagedal K, Ollinger K. Cytosolic acidification and lysosomal alkalinization during TNF-alpha induced apoptosis in U937 cells. Apoptosis 2006 May 9.
90. Li J, Eastman A. Apoptosis in an interleukin-2-dependent cytotoxic T lymphocyte cell line is associated with intracellular acidification. Role of the Na(+)/H(+)-antiport. J Biol Chem 1995; 270(7): 3203-3211.
91. Park HJ, Makepeace CM, Lyons JC, Song CW. Effect of intracellular acidity and ionomycin on apoptosis in HL-60 cells. Eur J Cancer 1996; 32A(3): 540-546.
92. Hirpara JL, Clement MV, Pervaiz S. Intracellular acidification triggered by mitochondrial-derived hydrogen peroxide is an effector mechanism for drug-induced apoptosis in tumor cells. J Biol Chem 2001; 276(1): 514-521.
93. Hendrix A, Westbroek W, Bracke M, De Wever O. An ex(o)citing machinery for invasive tumor growth. Cancer Res 2010; 70(23): 9533-9537.
94. Al-Nedawi K, Meehan B, Rak J. Microvesicles: messengers and mediators of tumor progression. Cell Cycle 2009; 8(13): 2014-2018.
95. Iero M, Valenti R, Huber V, et al. Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ 2008; 15(1): 80-88.
96. Parolini I, Federici C, Raggi C, et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem 2009; in press.
97. Hood JL, San RS, Wickline SA. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res 2011; 71(11): 3792-3801.
98. Grange C, Tapparo M, Collino F, et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res 2011; 71(15): 5346-5356.
99. Lardner A. The effects of extracellular pH on immune function. J Leukoc Biol 2001; 69(4): 522-530.
100. Severin T, Muller B, Giese G, et al. pH-dependent LAK cell cytotoxicity. Tumour Biol 1994; 15(5): 304-310.
101. Loeffler DA, Juneau PL, Heppner GH. Natural killer-cell activity under conditions reflective of tumor micro-environment. Int J Cancer 1991; 48(6): 895-899.
102. Fischer K, Hoffmann P, Voelkl S, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 2007; 109(9): 3812-3819.
103. Chiche J, Brahimi-Horn MC, Pouyssegur J. Tumor hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J Cell Mol Med 2009 Dec 8.
104. Fais S. Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism. J Intern Med 2010; 267(5): 515-525.
105. Mattsson JP, Vaananen K, Wallmark B, Lorentzon P. Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases. Biochim Biophys Acta 1991; 1065(2): 261-268.
106. Moriyama Y, Patel V, Ueda I, Futai M. Evidence for a common binding site for omeprazole and N-ethylmaleimide in subunit A of chromaffin granule vacuolar-type H(+)-ATPase. Biochem Biophys Res Commun 1993; 196(2): 699-706.
107. Fellenius E, Berglindh T, Sachs G, et al. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase. Nature 1981; 290(5802): 159-161.
108. Wallmark B, Sachs G, Mardh S, Fellenius E. Inhibition of gastric (H+ + K+)-ATPase by the substituted benzimidazole, picoprazole. Biochim Biophys Acta 1983; 728(1): 31-38.
109. Shin JM, Vagin O, Munson K, Kidd M, Modlin IM, Sachs G. Molecular mechanisms in therapy of acid-related diseases. Cell Mol Life Sci 2008; 65(2): 264-281.
110. Vanderhoff BT, Tahboub RM. Proton pump inhibitors: an update. Am Fam Physician 2002; 66(2): 273-280.
111. Brandstrom A, Lindberg P, Junggren U. Structure activity relationships of substituted benzimidazoles. Scand J Gastroenterol Suppl 1985; 108: 15-22.
112. Kromer W. Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds. Digestion 1995; 56(6): 443-454.
113. Roche VF. The chemically elegant proton pump inhibitors. Am J Pharm Educ 2006; 70(5): 101.
114. Shin JM, Cho YM, Sachs G. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors. J Am Chem Soc 2004; 126(25): 7800-7811.
115. J. The proton-pump inhibitors: similarities and differences. Clin Ther 2000; 22(3): 266-280; discussion 265.
116. Hunt RH, Armstrong D, Yaghoobi M, James C. The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects. Aliment Pharmacol Ther 2010; 31(6): 648-657.
117. Andersson T, Rohss K, Bredberg E, Hassan-Alin M. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther 2001; 15(10): 1563-1569.
118. Andersson T, Weidolf L. Stereoselective disposition of proton pump inhibitors. Clin Drug Investig 2008; 28(5): 263-279.
119. Abelo A, Andersson TB, Antonsson M, Naudot AK, Skanberg I, Weidolf L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 2000; 28(8): 966-972.
120. Andersson T, Hassan-Alin M, Hasselgren G, Rohss K, Weidolf L. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001; 40(6): 411-426.
121. Fock KM, Ang TL, Bee LC, Lee EJ. Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? Clin Pharmacokinet 2008; 47(1): 1-6.
122. Thomson AB, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol 2010; 16(19): 2323-2330.
123. McCarthy DM. Adverse effects of proton pump inhibitor drugs: clues and conclusions. Curr Opin Gastroenterol 2010; 26(6): 624-631.
124. Hagiwara T, Mukaisho K, Nakayama T, Sugihara H, Hattori T. Long-term proton pump inhibitor administration worsens atrophic corpus gastritis and promotes adenocarcinoma development in Mongolian gerbils infected with Helicobacter pylori. Gut 2011; 60(5): 624-630.
125. Tsukamoto H, Mizoshita T, Sasaki M, et al. Long-term High-dose Proton Pump Inhibitor Administration to Helicobacter pylori-infected Mongolian gerbils Enhances Neuroendocrine tumor Development in the Glandular Stomach. Asian Pac J Cancer Prev 2011; 12(4): 1049-1054.
126. Chubak J, Boudreau DM, Rulyak SJ, Mandelson MT. Colorectal cancer risk in relation to use of acid suppressive medications. Pharmacoepidemiol Drug Saf 2009; 18(7): 540-544.
127. Garcia Rodriguez LA, Lagergren J, Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut 2006; 55(11): 1538-1544.
128. Poulsen AH, Christensen S, McLaughlin JK, et al. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. Br J Cancer 2009; 100(9): 1503-1507.
129. Robertson DJ, Larsson H, Friis S, Pedersen L, Baron JA, Sorensen HT. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology 2007; 133(3): 755-760.
130. van Soest EM, van Rossum LG, Dieleman JP, et al. Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol 2008; 103(4): 966-973.
131. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180(7): 713-718.
132. Santucci R, Leveque D, Kemmel V, et al. Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors. Anticancer Res 2010; 30(3): 963-965.
133. Santucci R, Leveque D, Lescoute A, Kemmel V, Herbrecht R. Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors. Anticancer Res 2010; 30(9): 3807-3810.
134. Suzuki K, Doki K, Homma M, et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 2009; 67(1): 44-49.
135. Vakily M, Amer F, Kukulka MJ, Andhivarothai N. Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis. J Clin Pharmacol 2005; 45(10): 1179-1186.
136. Whelan J, Hoare D, Leonard P. Omeprazole does not alter plasma methotrexate clearance. Cancer Chemother Pharmacol 1999; 44(1): 88-89.
137. Mizunashi K, Furukawa Y, Katano K, Abe K. Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 1993; 53(1): 21-25.
138. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008; 179(4): 319-326.
139. Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Med 2009; 122(10): 896-903.
140. Chen M, Zou X, Luo H, et al. Effects and mechanisms of proton pump inhibitors as a novel chemosensitizer on human gastric adenocarcinoma (SGC7901) cells. Cell Biol Int 2009; 33(9): 1008-1019.
141. Vishvakarma NK, Singh SM. Mechanisms of tumor growth retardation by modulation of pH regulation in the tumor-microenvironment of a murine T cell lymphoma. Biomed Pharmacother 2011; 65(1): 27-39.
142. Breedveld P, Pluim D, Cipriani G, et al. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 2005 Apr 1; 65(7): 2577-2582.
143. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 2001; 364(6): 551-557.
144. Gatlik-Landwojtowicz E, Aanismaa P, Seelig A. The rate of P-glycoprotein activation depends on the metabolic state of the cell. Biochemistry 2004 Nov 23; 43(46): 14840-14851.
145. Yeo M, Kim DK, Kim YB, et al. Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells. Clin Cancer Res 2004 Dec 15; 10(24): 8687-8696.
146. Scaringi L, Cornacchione P, Ayroldi E, et al. Omeprazole induces apoptosis in jurkat cells. Int J Immunopathol Pharmacol 2004 Sep-Dec; 17(3): 331-342.
147. Watts RN, Hackett JA, Zhang XD, Hersey P. Proton pump inhibitor omeprazole and NAC complex induces apoptosis in melanoma cell lines Pigment Cell. Melanoma Res 2010; 23(6): 985.
148. Der G. An overview of proton pump inhibitors. Gastroenterol Nurs 2003; 26(5): 182-190.
149. Ramdani A, Mignon M, Samoyeau R. Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome. Gastroenterol Clin Biol 2002; 26(4): 355-359.
150. Marino ML, Fais S, Djavaheri-Mergny M, et al. Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells. Cell Death Dis 2010; 1: e87.
151. Udelnow A, Kreyes A, Ellinger S, et al. Omeprazole inhibits proliferation and modulates autophagy in pancreatic cancer cells. PLoS One 2011; 6(5): e20143.
152. Balgi AD, Diering GH, Donohue E, et al. Regulation of mTORC1 Signaling by pH. PLoS One 2011; 6(6): e21549.
153. Amaravadi RK, Yu D, Lum JJ, et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 2007; 117(2): 326-336.
154. White E, DiPaola RS. The double-edged sword of autophagy modulation in cancer. Clin Cancer Res 2009; 15(17): 5308-5316.
155. Kountouras J, Boura P, Apostolides G, Zaharioudaki E, Tsapas G. In vivo effect of omeprazole on HLA-DR expression and the monocyte-macrophage function in patients with duodenal ulcer disease. Immunopharmacol Immunotoxicol 1994; 16(3): 437-448.
156. Vishvakarma NK, Singh SM. Immunopotentiating effect of proton pump inhibitor pantoprazole in a lymphoma-bearing murine host: Implication in antitumor activation of tumor-associated macrophages. Immunol Lett 2010; 134(1): 83-92.
157. Singer K, Kastenberger M, Gottfried E, et al. Warburg phenotype in renal cell carcinoma: high expression of glucose-transporter 1 (GLUT-1) correlates with low CD8(+) T-cell infiltration in the tumor. Int J Cancer 2011; 128(9): 2085-2095.
158. Kim YJ, Lee JS, Hong KS, Chung JW, Kim JH, Hahm KB. Novel application of proton pump inhibitor for the prevention of colitis-induced colorectal carcinogenesis beyond acid suppression. Cancer Prev Res (Phila) 2010; 3(8): 963-974.
159. Watson SA, Smith AM. Hypergastrinemia promotes adenoma progression in the APC(Min-/+) mouse model of familial adenomatous polyposis. Cancer Res 2001; 61(2): 625-631.
160. Islami F, Kamangar F, Boffetta P. Use of proton pump inhibitors and risk of progression of Barrett's esophagus to neoplastic lesions. Am J Gastroenterol 2009; 104(10): 2646-2648.
161. Chen S, Song X, Gao X, et al. Proton pump inhibitors and the risk of colorectal cancer: a meta-analysis. J Clin Gastroenterol 2011; 45(2): 177.
162. Yang YX, Hennessy S, Propert K, Hwang WT, Sedarat A, Lewis JD. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology 2007; 133(3): 748-754.